Delving into the Latest Updates on Pavlov First Saint Petersburg State Medical University with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Immune System Diseases

Blood components

Monoclonal antibody

Biosimilar

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Biosimilar	1
Blood components	1
Monoclonal antibody	1

Top 5 Target	Count

VEGF-A(Vascular endothelial growth factor A)	1

This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal cancer with mutations in KRAS or NRAS genes. The hypotheses of this study are that a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab (compared to regorafenib) prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.

Start Date17 Mar 2025

Sponsor / Collaborator

Pavlov First Saint Petersburg State Medical University

NCT06873282

/ CompletedPhase 2IIT

Randomized, Double-blind, Placebo-controlled Phase 2 Trial of ТВ/Flu-05Е Intranasal Vector Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years

The aim of the study is to investigate immunogenicity and safety of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years

Start Date13 Dec 2023

Sponsor / Collaborator

Research Institute of Influenza

[+1]

NCT06890429

/ CompletedPhase 2IIT

Randomized, Double-blind, Placebo-controlled Phase 2 Trial of RSV/Flu-01E Vaccine for the Prevention of Respiratory Syncytial Virus Infection in Volunteers Over 60 Years

The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years

Start Date07 Dec 2023

Sponsor / Collaborator

Research Institute of Influenza

[+1]

100 Clinical Results associated with Pavlov First Saint Petersburg State Medical University

Login to view more data

0 Patents (Medical) associated with Pavlov First Saint Petersburg State Medical University

Login to view more data

2,492

Literatures (Medical) associated with Pavlov First Saint Petersburg State Medical University

31 Dec 2025·The Journal of Maternal-Fetal & Neonatal Medicine

Cerebral vein thrombosis: management tactics with a focus on pregnancy, the use of hormone therapy and assisted reproductive technologies

Review

Author: Vorobev, Alexander ; Makatsariya, Nataliya ; Grigoreva, Kristina ; Zainulina, Marina ; Gris, Jean-Christophe ; Gashimova, Nilufar ; Akinshina, Svetlana ; Elalamy, Ismail ; Kapanadze, Daredzhan ; Yagubova, Fidan ; Solopova, Alina ; Zubenko, Vladislav ; Bitsadze, Viktoria ; Gerotziafas, Grigoris ; Mashkova, Tamara ; Tsibizova, Valentina ; Makatsariya, Alexander ; Valikhanova, Lala ; Tretyakova, Maria ; Khizroeva, Jamilya

Purpose: Cerebral vein thrombosis is a rare, life-threatening condition that has now become more commonly diagnosed due to advancements in imaging techniques. Our purpose is to improve understanding of pathogenesis, diagnosis and pregnancy and IVF management in patients with a history of cerebral thrombosis.Materials and methods: We present an overview of the modern tactics of anticoagulant therapy for cerebral thrombosis with a focus on pregnancy, the use of hormone therapy, and assisted reproductive technologies.Results: The most common risk factors for cerebral vein thrombosis are pregnancy, the postpartum period, and the use of oral contraceptives, which explains the high incidence of this pathology in women. The development of cerebral thrombosis is a vivid example of the interaction and synergetic effects of persistent factors that cause an increased risk of thrombotic complications, which include thrombophilia and acquired risk factors. Despite the possible risks, pregnancy after previously suffered cerebral thrombosis is not contraindicated provided adequate anticoagulant therapy.Conclusions: The most common provoking factors for the development of cerebral thrombosis in women are pregnancy and the use of estrogen-containing drugs. The issue of thromboprophylaxis during pregnancy, when using ART methods and the possibility of using hormonal therapy after cerebral vein thrombosis requires further study.

01 Aug 2025·Journal of Critical Care

Renal replacement therapy modalities and techniques in intensive care units: An international survey

Article

Author: Milet, Igor ; Wu, Vin-Cent ; Sokolov, Dmitry ; Marel, Arnaud ; Mehta, Ravindra ; Garcia, Xaime ; Ostermann, Marlies ; Monard, Céline ; Joannidis, Michael ; Premuzic, Vedran ; Doi, Kent ; Schneider, Antoine ; Rimmelé, Thomas ; Mc Nicholas, Bairbre ; Romain, Marc ; Zarbock, Alexander ; Peng, Zhiyong ; Reis, Thiago ; Pizarro, Camilo ; Bellomo, Rinaldo ; Bobek, Ilona ; De Rosa, Silvia

BACKGROUND AND HYPOTHESISUp to 14 % of critically ill patients receive renal replacement therapy (RRT) during their ICU stay and are treated with intermittent hemodialysis (IHD) or one of the continuous renal replacement therapy (CRRT) techniques. The choice of a modality (IHD or CRRT) and technique (continuuous veno-venous -hemodialysis (CVVHD), -hemofiltration (CVVH), or - hemodiafiltration (CVVHDF)), and the way it is delivered, may have an impact on outcomes but only few studies addressed this question. We aimed to survey the availability, settings, and clinicians' preferences regarding RRT modalities and techniques in critically ill patients.METHODSBetween July 2021 and March 2022, we conducted an open online worldwide survey targeting ICU clinicians and consisting of 31 questions.RESULTSAmong the 1174 participants from 73 countries, 94 % indicated their ability to initiate RRT at any time. CRRT was more widely available than IHD (97 % vs 85 %). CVVHDF was the most frequently used CRRT technique (59 %), followed by CVVHD (26 %) and CVVH (16 %). Most participants (70 %) reported having access to at least two CRRT techniques in their unit. Preference for IHD or CRRT varied greatly, depending on the clinical situation. Among CRRT techniques, CVVHD was preferred for removal of small-sized molecules, better hemofilter lifespan and reduced nursing workload. The preferential indications for CVVH included septic shock, removal of middle-sized molecules and fluid overload. The technical settings for CVVH and CVVHDF were very heterogeneous.CONCLUSIONThis international survey underscores the large diversity in RRT practices wordlwide, as well as heterogeneity in beliefs and preferences among intensivists. These data highlight the need for robust comparative trials to identify the optimal RRT modality and technique to improve outcomes in specific clinical situations.

04 May 2025·Fullerenes, Nanotubes and Carbon Nanostructures

Cytotoxicity and photothermal properties of graphene oxide conjugate with folic acid and a cytostatic agent of styryl thiazolopyrimidinium class

Author: Grishacheva, Tatiana G. ; Semenov, Konstantin N. ; Shemchuk, Olga S. ; Murin, Igor V. ; Maistrenko, Dmitriy N. ; Sharoyko, Vladimir V. ; Paponov, Boris V. ; Molchanov, Oleg E. ; Iurev, Gleb O.

In recent years, the field of nanomedicine has garnered significant attention, particularly in the development of advanced drug delivery systems.Among the promising materials, highly oxidized graphene oxide (GO) has emerged as key components due to unique physicochem. properties and biocompatibility.These materials offer novel avenues for targeted drug delivery, enhancing therapeutic efficacy while minimizing side effects.This article explores the innovative design of nanoparticle-based drug delivery systems utilizing highly oxidized graphene oxide with folic acid in combination with thiazolopyrimidinium salt, highlighting their potential applications in medicine.

100 Deals associated with Pavlov First Saint Petersburg State Medical University

Login to view more data

100 Translational Medicine associated with Pavlov First Saint Petersburg State Medical University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Phase 3 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bevacizumab biosimilar(Biocad Medical, Inc.) ( VEGF-A )	Non-Small Cell Lung Cancer More	Phase 3
Allogeneic platelet lysate(Pavlov First Saint Petersburg State Medical University)	Chronic graft-versus-host disease More	Phase 2